The Next Industrial Revolution: Computational Biology & Bioplatforms

NFX Bio: Investing in Scientist-Founders from the Very Beginning with Omri Amirav-Drory

A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D

Why C2i is the World’s First Platform for Cancer Intelligence

The Business Case for Longevity

A Scientific Approach To Your Company (And Your Life)

What I Wish I Knew as a Scientist-Founder

A Scientific Approach to VC

The Future of Longevity: The Battle Against Human Aging (An NFX Documentary)

Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Delivery

The Future of Longevity: Keeping Healthy People Healthy

The 3 Waves of AI in Bio

Maximizing TechBio Deal Potential: Platform vs. Asset Deals

Deal or Die: Your 3-Part Guide to Business Development in TechBio

Tech Founders, Don’t Be Afraid of Bio

What Doesn’t Kill You, Mutates And Tries Again

From Sick Care to Health Care: Why We Need Longevity Startups

How to Prove Your TechBio Platform at Seed Stage

Why NFX Invested in Centivax: The TechBio Platform Developing Universal Vaccines

Academia or Startup? A Decision Matrix for Future Scientist-Founders

The Golden Ratio: Navigating East Coast v. West Coast in TechBio Investing

From Biotech to TechBio

Why NFX Invested in Pangea Biomed, the Startup Matching Cancer Patients with the Right Therapies

Why NFX Invested in Pepper Bio: The ‘Waze for Drug Discovery’ Will Treat the Untreatable